The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease

Journal of Medicinal Chemistry

Volumn 48, Issue 17, 2005, Pages 5415-5418

  Hucke, Oliver ^a   Gelb, Michael H ^a,b   Verlinde, Christophe L M J ^a,b   Buckner, Frederick S ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRIOL; FLUCONAZOLE; LANOSTEROL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; STEROL 14ALPHA DEMETHYLASE; TIPIFARNIB;

ARTICLE; CHAGAS DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; NONHUMAN; PARASITE DEVELOPMENT; TRYPANOSOMA CRUZI;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BINDING SITES; CHAGAS DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LANOSTEROL; MODELS, MOLECULAR; OXIDOREDUCTASES; PROTEIN BINDING; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 23944466866     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050441z     Document Type: Article

References (17)

1. Buckner, F. S.; Eastman, R. T.; Nepomuceno-Silva, J. L.; Speelmon, E. C.; Myler, P. J.; et al. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol. Biochem. Parasitol. 2002, 122, 181-188.
2. Sebti, S. M.; Adjei, A. A. Farnesyltransferase inhibitors. Sem. Oncol. 2004, 31, 28-39.
3. Buckner, F.; Yokoyama, K.; Lockman, J.; Aikenhead, K.; Ohkanda, J.; et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 15149-15153.
4. Sali, A.; Blundell, T. L. Comparative Protein Modeling by Satisfaction of Spatial Restraints. J. Mol. Biol. 1993, 234, 779-815.
5. Podust, L. M.; Poulos, T. L.; Waterman, M. R. Crystal structure of cytochrome P450 14 alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3068-3073.
6. Buckner, F. S.; Joubert, B. M.; Boyle, S. M.; Eastman, R. T.; Verlinde, C. L. M. J.; et al. Cloning and analysis of Trypanosoma cruzi lanosterol 14 alpha-demethylase. Mol. Biochem. Parasitol. 2003, 132, 75-81.
7. Podust, L. M.; Yermalitskaya, L. V.; Lepesheva, G. I.; Podust, V. N.; Dalmasso, E. A.; et al. Estriol bound and ligand-free structures of sterol 14 alpha-demethylase. Structure 2004, 12, 1937-1945.
8. McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.
9. Ji, H. T.; Zhang, W. N.; Zhou, Y. J.; Zhang, M.; Zhu, J.; et al. A three-dimensional model of lanosterol 14 alpha-demethylase of Candida albicans and its interaction with azole antifungals. J. Med. Chem. 2000, 43, 2493-2505.
10. Podust, L. M.; Stojan, J.; Poulos, T. L.; Waterman, M. R. Substrate recognition sites in 14 alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J. Inorg. Biochem. 2001, 87, 227-235.
11. Sheng, C. Q.; Zhang, W. N.; Zhang, M.; Song, Y. L.; Ji, H. T.; et al. Homology modeling of lanosterol 14 alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate interactions. J. Biomol. Struct. Dyn. 2004, 22, 91-99.
12. Lepesheva, G. I.; Nes, W. D.; Zhou, W. X.; Hill, G. C.; Waterman, M. R. CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochemistry 2004, 43, 10789-10799.
13. Kurzrock, R.; Albitar, M.; Cortes, J. E.; Estey, E. H.; Faderl, S. H.; et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 2004, 22, 1287-1292.
14. Reid, T. S.; Beese, L. S. Crystal structures of the anticancer clinical candidates R1 15777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochemistry 2004, 43, 6877-6884.
15. Crul, M.; de Klerk, G. J.; Swart, M.; van't Veer, L. J.; de Jong, D.; et al. Phase I clinical and pharmacologie study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 2002, 20, 2726-2735.
16. Lebowitz, P. F.; Eng-Wong, J.; Widemann, B. C.; Balis, F. M.; Jayaprakash, N.; et al. A phase I trial and pharmacokinetic study of tipifarnib, a farnsyltransferase inhibitor, and tamoxofen in metastatic breast cancer. Clin. Cancer Res. 2005, 11, 1247-1252.
17. Venet, M.; End, D.; Angibaud, P. Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery. Curr. Top. Med. Chem. 2003, 3, 1095-1102.